Regulation of ABCA1-mediated cholesterol efflux by sphingosine-1-phosphate signaling in macrophages

Vaidya, Mithila; Jentsch, Julian A.; Peters, Susann; Keul, Petra; Weske, Sarah; Gräler, Markus H.; Mladenov, Emil; Iliakis, George; Heusch, Gerd; Levkau, Bodo

doi:10.1194/jlr.m088443

Cited by 40 publications

(39 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Small animals such as mice, rats and rabbits are often used due to ease of breeding, short gestation and life cycle, although they are naturally resistant to develop hypercholesterolaemia and atherosclerosis. While rodents show low expression/absence of cholesteryl ester transfer protein (CETP), rabbits have higher CETP activity, thereby higher LDL and low HDL levels representing a more useful animal model for hypercholesterolaemia research (Tsutsumi, Hagi, & Inoue, 2001).…”

Section: Small Animals (Mice Rats and Rabbits)mentioning

confidence: 99%

“…Large animals such as dogs and pigs under normal chow exhibit a high HDL-c/low LDL-c profile during their life span, associated with a low cardiovascular risk (Tsutsumi et al, 2001;Yin et al, 2012). Spontaneous atherosclerosis in dog is rare, while it can be found in pigs depending on age and strain.…”

Section: Large Animals (Diet and Genetic) Of High Tc And High Ldlmentioning

confidence: 99%

“…HDL‐c exerts cardio/vascular‐protective properties by taking part in reverse cholesterol transport, from cholesterol efflux (Vaidya et al, 2019), lipoprotein remodelling to hepatic lipid uptake and clearance (Favari et al, 2015). Accordingly, HDL levels have been inversely related to cardiovascular risk and atherosclerosis development.…”

Section: Animal Models For Hdl Metabolismmentioning

confidence: 99%

See 2 more Smart Citations

Hyperlipidaemia and cardioprotection: Animal models for translational studies

Andreadou

Schulz

Badimon

et al. 2020

British J Pharmacology

Self Cite

View full text Add to dashboard Cite

Hyperlipidaemia is a well‐established risk factor for cardiovascular diseases and therefore, many animal model have been developed to mimic the human abnormal elevation of blood lipid levels. In parallel, extensive research for the alleviation of ischaemia/reperfusion injury has revealed that hyperlipidaemia is a major co‐morbidity that attenuates the cardioprotective effect of conditioning strategies (preconditioning, postconditioning and remote conditioning) and that of pharmacological interventions by interfering with cardioprotective signalling pathways. In the present review article, we summarize the existing data on animal models of hypercholesterolaemia (total, low density and HDL abnormalities) and hypertriglyceridaemia used in ischaemia/reperfusion injury and protection from it. We also provide recommendations on preclinical animal models to be used for translations of the cardioprotective strategies into clinical practice.LINKED ARTICLESThis article is part of a themed issue on Risk factors, comorbidities, and comedications in cardioprotection. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v177.23/issuetoc

show abstract

Section: Small Animals (Mice Rats and Rabbits)mentioning

confidence: 99%

Section: Large Animals (Diet and Genetic) Of High Tc And High Ldlmentioning

confidence: 99%

Section: Animal Models For Hdl Metabolismmentioning

confidence: 99%

See 1 more Smart Citation

Hyperlipidaemia and cardioprotection: Animal models for translational studies

Andreadou

Schulz

Badimon

et al. 2020

British J Pharmacology

Self Cite

View full text Add to dashboard Cite

show abstract

“…S1P may be effluxed to extracellular plasma acceptors, i.e., either plasma nonlipoprotein or lipoprotein carriers [30]. In this regard, S1P can be effluxed to plasma HDL [153], in a process that is mainly mediated by the action of apolipoprotein (Apo)M [154].…”

Section: Hdl-bound S1p and Apolipoprotein (Apo)mmentioning

confidence: 99%

Novel Insights into the Role of HDL-Associated Sphingosine-1-Phosphate in Cardiometabolic Diseases

Diarte-Añazco

Méndez-Lara

Pérez

et al. 2019

IJMS

View full text Add to dashboard Cite

Sphingolipids are key signaling molecules involved in the regulation of cell physiology. These species are found in tissues and in circulation. Although they only constitute a small fraction in lipid composition of circulating lipoproteins, their concentration in plasma and distribution among plasma lipoproteins appears distorted under adverse cardiometabolic conditions such as diabetes mellitus. Sphingosine-1-phosphate (S1P), one of their main representatives, is involved in regulating cardiomyocyte homeostasis in different models of experimental cardiomyopathy. Cardiomyopathy is a common complication of diabetes mellitus and represents a main risk factor for heart failure. Notably, plasma concentration of S1P, particularly high-density lipoprotein (HDL)-bound S1P, may be decreased in patients with diabetes mellitus, and hence, inversely related to cardiac alterations. Despite this, little attention has been given to the circulating levels of either total S1P or HDL-bound S1P as potential biomarkers of diabetic cardiomyopathy. Thus, this review will focus on the potential role of HDL-bound S1P as a circulating biomarker in the diagnosis of main cardiometabolic complications frequently associated with systemic metabolic syndromes with impaired insulin signaling. Given the bioactive nature of these molecules, we also evaluated its potential of HDL-bound S1P-raising strategies for the treatment of cardiometabolic disease.

show abstract

“…After endogenous S1P generated by SphK2 binds to and activates S1PR3, both transcriptional and functional ABCA1 regulatory pathways are active in mediating cholesterol outflow in a positive feedback loop (Figure 4B). 76 …”

Section: S1p‐s1prs Signalling In Cardiovascular Diseasesmentioning

confidence: 99%

The role of sphingosine 1‐phosphate and its receptors in cardiovascular diseases

Ouyang

Shu

Chen

et al. 2020

J Cellular Molecular Medi

View full text Add to dashboard Cite

There are many different types of cardiovascular diseases, which impose a huge economic burden due to their extremely high mortality rates, so it is necessary to explore the underlying mechanisms to achieve better supportive and curative care outcomes. Sphingosine 1‐phosphate (S1P) is a bioactive lipid mediator with paracrine and autocrine activities that acts through its cell surface S1P receptors (S1PRs) and intracellular signals. In the circulatory system, S1P is indispensable for both normal and disease conditions; however, there are very different views on its diverse roles, and its specific relevance to cardiovascular pathogenesis remains elusive. Here, we review the synthesis, release and functions of S1P, specifically detail the roles of S1P and S1PRs in some common cardiovascular diseases, and then address several controversial points, finally, we focus on the development of S1P‐based therapeutic approaches in cardiovascular diseases, such as the selective S1PR1 modulator amiselimod (MT‐1303) and the non‐selective S1PR1 and S1PR3 agonist fingolimod, which may provide valuable insights into potential therapeutic strategies for cardiovascular diseases.

show abstract

Regulation of ABCA1-mediated cholesterol efflux by sphingosine-1-phosphate signaling in macrophages

Cited by 40 publications

References 43 publications

Hyperlipidaemia and cardioprotection: Animal models for translational studies

Hyperlipidaemia and cardioprotection: Animal models for translational studies

Novel Insights into the Role of HDL-Associated Sphingosine-1-Phosphate in Cardiometabolic Diseases

The role of sphingosine 1‐phosphate and its receptors in cardiovascular diseases

Contact Info

Product

Resources

About